Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS staff to get a minimum of 4,71 percent salary increase
2005-11-25

The University of the Free State (UFS) management and trade unions have agreed on a minimum of 4,71 percent salary increase for 2006 as well as a once-off non-pensionable bonus of R1200 payable in December 2005.

The agreement was signed today by representatives of the UFS management and the trade unions, UVPERSU and NEHAWU, in Bloemfontein.

Prof Niel Viljoen, Chief Director: Operations at the UFS and chairperson of the UFS Council’s representatives, and Prof Johan Grobbelaar, chairperson of the joint Union Forum, said: “The bonus is payable in December 2005 in recognition of the role that staff played during the year to promote the UFS as a university of excellence.”

He said the intention is to pass the maximum benefit possible on to staff without exceeding the limits of financial sustainability of the institution.
For this reason the negotiating parties reaffirmed their commitment to the Multiple-year Income-related Remuneration Improvement Model used as a framework for negotiations.

Proff Viljoen and Prof Grobbelaar said one of the factors that influence the model and therefore the negotiations is the level of subsidy the UFS receives from the government.

“As the state subsidy level is unfortunately not yet known, remuneration could vary several percentage points between a window of 4,71 and 5,5 percent. Should the state subsidy be such that the increase would fall outside this window then the parties will renegotiate.”

Proff  Viljoen and Prof Grobbelaar said the R1200 bonus is payable to staff members who were in the employ of the UFS on UFS conditions of service on 21 November 2005 and who assumed duties before 1 October 2005. There are however some exceptions.

The agreement signed today also provides for restructuring funds of R752 000 to address partial backlogs in support services, including an increase in the medical allowance of 640 staff members.

The implementation date for the salary adjustment is 1 January 2006, but could be implemented on a later date due to logistical arrangements.

Proff Viljoen and Prof Grobbelaar said the UFS and unions could reach an agreement despite the declining phase in income and the generally more difficult financial environment in which universities operate.

Prof Grobbelaar said salary negotiations are never easy, but the model is an important tool. The model made it possible to tie up salary negotiations for November 2006. “This is unique for any higher education institution.”

Media release
Issued by: Lacea Loader
Media Representative
Tel:  (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
24 November 2005

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept